big changes in treating chronic hepatitis C with two new oral antivirals, Olysio (simeprevir) and Sovaldi (sofosbuvir)

February 2014

You'll see big changes in treating chronic hepatitis C with two new oral antivirals, Olysio (simeprevir) and Sovaldi (sofosbuvir).

These new drugs...and others in the pipeline...will make it easier for primary care providers to treat hepatitis C. Eventually simpler oral regimens will replace interferon...and be better tolerated.

Olysio (oh-LI-see-oh) is a new oral PROTEASE inhibitor...and will be added to injectable interferon and oral ribavirin.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber's Letter includes:

12 issues every year, with brief articles about new meds and guidelines
48+ CE courses, including the popular CE-in-the-Letter
Quick reference drug comparison charts
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

Cardiology controversy about when it's acceptable to aim for HIGHER blood pressure goals
Cardiology MORE med choices for the initial treatment of UNCOMPLICATED hypertension
Gastroenterology The new PPI esomeprazole STRONTIUM will cause some confusion
Hepatitis C big changes in treating chronic hepatitis C with two new oral antivirals, Olysio (simeprevir) and Sovaldi (sofosbuvir)
NSAIDs A new version of oral diclofenac for pain called Zorvolex (ZOR-voh-lex) will hit the market
Inhalers Patients will ask more questions about how to use their inhalers
Vaccines when it's okay to give vaccines to immunocompromised patients and their household contacts
Allergic Reactions fewer red flags when you prescribe celecoxib (Celebrex) to patients with a sulfa allergy
Antibacterials whether "antibacterial" soaps and washes are safe and more effective than plain soap and water
Back Pain many therapies CAN help patients with CHRONIC lower back pain
Alzheimer's Disease taking high doses of vitamin E to slow the progression of Alzheimer's disease

big changes in treating chronic hepatitis C with two new oral antivirals, Olysio (simeprevir) and Sovaldi (sofosbuvir)

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Table of Contents